(19)
(11) EP 4 562 151 A1

(12)

(43) Date of publication:
04.06.2025 Bulletin 2025/23

(21) Application number: 23754431.7

(22) Date of filing: 27.07.2023
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
C12P 21/02(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/1137; C12N 15/1138; C12N 2310/141; C12N 9/14; C12Y 306/01005
(86) International application number:
PCT/IB2023/057614
(87) International publication number:
WO 2024/023746 (01.02.2024 Gazette 2024/05)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 29.07.2022 US 202263369841 P
07.07.2023 US 202363512316 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • AUSLAENDER, David
    4002 Basel (CH)
  • LEBESGUE, Nicolas
    4002 Basel (CH)
  • OBRDLIK, Petr
    4002 Basel (CH)
  • TAPPAREL, Joël Aloïs René
    4002 Basel (CH)
  • WAGNER, Nina
    4002 Basel (CH)

(74) Representative: Bieri, Simona Roxana et al
Novartis Pharma AG Patent Department Lichtstrasse 35
4056 Basel
4056 Basel (CH)

   


(54) IMPROVED PRODUCTION OF CD39 VARIANTS